Drugs / TCM Formula
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07597850 | Apr → Oct 2026 expected | muscular atrophy, osteoporosis | Tri-Service General Hospital (TSGH) | Recruiting | No outcome recorded |
| Phase 2 | NCT05229029 | Apr 2020 → Sep 2023 | cancer-related condition | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05204758 | May 2016 → Dec 2017 | lung adenocarcinoma | China Medical University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCM Formula | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05229029 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Traditional Chinese Medicine (TCM) facilitates the treatment of lung cancer” NCT05204758 ↗ |
| Route | Oral | “Patients were instructed to intake three packages of TCM preparations with each meal three times a day” NCT05204758 ↗ |